Bismuth subsalicylate: Difference between revisions
(Marked this version for translation)
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
==Administration==
<languages/>
*Type: Anti-[[diarrhea]]l
<translate>
 
==Administration== <!--T:1-->
 
<!--T:2-->
*Type: Anti-[[Special:MyLanguage/diarrhea|diarrhea]]l
*Dosage Forms:
*Dosage Forms:
*Routes of Administration: PO
*Routes of Administration: PO
*Common Trade Names: Pepto Bismol, Maalox
*Common Trade Names: Pepto Bismol, Maalox


==Adult Dosing==
*[[Diarrhea]], gas, indigestion, heartburn, [[nausea]]: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily
*[[H. pylori]]: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist


==Pediatric Dosing==
==Adult Dosing== <!--T:3-->
 
<!--T:4-->
*[[Special:MyLanguage/Diarrhea|Diarrhea]], gas, indigestion, heartburn, [[Special:MyLanguage/nausea|nausea]]: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily
*[[Special:MyLanguage/H. pylori|H. pylori]]: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist
 
 
==Pediatric Dosing== <!--T:5-->
 
<!--T:6-->
*<3y: safety/efficacy not established
*<3y: safety/efficacy not established
*2-6y: 87mg PO q30-60m PRN
*2-6y: 87mg PO q30-60m PRN
Line 16: Line 27:
*>12y: adult dose
*>12y: adult dose


==Special Populations==
 
===[[Drug pregnancy categories|Pregnancy Rating]]===
==Special Populations== <!--T:7-->
 
 
===[[Special:MyLanguage/Drug pregnancy categories|Pregnancy Rating]]=== <!--T:8-->
 
<!--T:9-->
*Category C, Category D in 3rd trimester
*Category C, Category D in 3rd trimester


===Lactation risk===
 
===Lactation risk=== <!--T:10-->
 
<!--T:11-->
*Salicylates enter breastmilk; use with caution
*Salicylates enter breastmilk; use with caution


===Renal Dosing===
 
===Renal Dosing=== <!--T:12-->
 
<!--T:13-->
*Caution: overdose may cause nephrotoxicity
*Caution: overdose may cause nephrotoxicity


===Hepatic Dosing===


==Contraindications==
===Hepatic Dosing=== <!--T:14-->
 
 
==Contraindications== <!--T:15-->
 
<!--T:16-->
*Allergy to class/drug
*Allergy to class/drug
*Infectious diarrhea (fever)
*Infectious diarrhea (fever)
*von Willebrand disease, hemorrhage, ulcer, GI bleeding, hemophilia
*von Willebrand disease, hemorrhage, ulcer, GI bleeding, hemophilia
*In pediatric patients; chicken pox or influenza (risk of [[Reye syndrome]])
*In pediatric patients; chicken pox or influenza (risk of [[Special:MyLanguage/Reye syndrome|Reye syndrome]])
 
 
==Adverse Reactions== <!--T:17-->
 
 
===Serious=== <!--T:18-->


==Adverse Reactions==
<!--T:19-->
===Serious===
*Duodenal ulcer, GI hemorrhage
*Duodenal ulcer, GI hemorrhage
*Neurotoxicity
*Neurotoxicity
*Renal failure
*Renal failure


===Common===
 
===Common=== <!--T:20-->
 
<!--T:21-->
*Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort
*Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort
*Black stool, melena
*Black stool, melena
Line 52: Line 86:
*Muscle spasm
*Muscle spasm


==Pharmacology==
 
==Pharmacology== <!--T:22-->
 
<!--T:23-->
*Half-life: Bismuth- 21-72 days, salicylate- 2.5h
*Half-life: Bismuth- 21-72 days, salicylate- 2.5h
*Metabolism: GI tract, liver
*Metabolism: GI tract, liver
*Excretion: Bismuth- feces, salicylate- urine
*Excretion: Bismuth- feces, salicylate- urine


==Mechanism of Action==
 
==Mechanism of Action== <!--T:24-->
 
<!--T:25-->
*Bismuth: antimicrobial, anti-inflammatory action
*Bismuth: antimicrobial, anti-inflammatory action
*Salicylate: antisecretory effect
*Salicylate: antisecretory effect


==Comments==
 
==Comments== <!--T:26-->
 
 
==See Also== <!--T:27-->
 
<!--T:28-->
*[[Special:MyLanguage/Bismuth toxicity|Bismuth toxicity]]




==See Also==
==References== <!--T:29-->
*[[Bismuth toxicity]]


==References==
<!--T:30-->
https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10
https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10
<references/>
<references/>


<!--T:31-->
[[Category:Pharmacology]]
[[Category:Pharmacology]]
[[Category:GI]]
[[Category:GI]]
</translate>

Latest revision as of 21:25, 6 January 2026

Other languages:

Administration

  • Type: Anti-diarrheal
  • Dosage Forms:
  • Routes of Administration: PO
  • Common Trade Names: Pepto Bismol, Maalox


Adult Dosing

  • Diarrhea, gas, indigestion, heartburn, nausea: 524mg (2 tabs regular strength) PO q30m PRN, max 8 doses regular strength or 4 doses extra-strength daily
  • H. pylori: 524mg (2 regular-strength tablets or 1 extra-strength tablet) + 250 mg metronidazole + 500 mg tetracycline PO q6hr x14d, plus H2 antagonist


Pediatric Dosing

  • <3y: safety/efficacy not established
  • 2-6y: 87mg PO q30-60m PRN
  • 6-9y: 175mg PO q30-60m PRN
  • 9-12y: 262mg PO q30-60m PRN
  • >12y: adult dose


Special Populations

Pregnancy Rating

  • Category C, Category D in 3rd trimester


Lactation risk

  • Salicylates enter breastmilk; use with caution


Renal Dosing

  • Caution: overdose may cause nephrotoxicity


Hepatic Dosing

Contraindications

  • Allergy to class/drug
  • Infectious diarrhea (fever)
  • von Willebrand disease, hemorrhage, ulcer, GI bleeding, hemophilia
  • In pediatric patients; chicken pox or influenza (risk of Reye syndrome)


Adverse Reactions

Serious

  • Duodenal ulcer, GI hemorrhage
  • Neurotoxicity
  • Renal failure


Common

  • Nausea, diarrhea, abdominal pain, constipation, anorexia, dyspepsia, flatulence, anal discomfort
  • Black stool, melena
  • URI, sinusitis
  • Asthenia
  • Discolored tongue, taste perversion
  • Headache, dizziness
  • Paresthesia
  • Anxiety, depression
  • Tinnitus
  • Muscle spasm


Pharmacology

  • Half-life: Bismuth- 21-72 days, salicylate- 2.5h
  • Metabolism: GI tract, liver
  • Excretion: Bismuth- feces, salicylate- urine


Mechanism of Action

  • Bismuth: antimicrobial, anti-inflammatory action
  • Salicylate: antisecretory effect


Comments

See Also


References

https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037#10

Retrieved from "https://www.wikem.org/w/index.php?title=Bismuth_subsalicylate&oldid=380140"